Direkt zum Inhalt
Merck

G005819

LC/MS (TOF) Analysis of Antiarrhythmic Drugs and Metabolites on Ascentis® Express HILIC: Improvement in Analyte Response after Solid Phase Extraction (SPE) using HybridSPE®-Phospholipid

application for HPLC, application for SPE

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Methode(n)

HPLC: suitable
solid phase extraction (SPE): suitable

Testparameter

sample preparation: SPE (Solid Phaes Extraction)
sample: rat plasma was spiled directly from stock standard to a level of 400 ng/mL
SPE tube/cartridge: HybridSPE-Phospholipid 96-Well Plate, 50 mg/2 mL (575656-U)
sample addition: apply 100 μL of plasma to plate, followed by 300 μL of 1% formic acid acetonitrile. Agitate via vortex for 4 min
elution: place on vacuum manifold and apply 10" Hg vacuum for 4 minutes. Collect filtrate and analyze directly.
column: Ascentis Express HILIC, 10 cm x 2.1 mm I.D., 2.7 μm particles (53939-U)
mobile phase: [A] 5 mM ammonium formate; [B] 5 mM ammonium formate in acetonitrile; (5:95, A:B, pH 7.0 with formic acid)
flow rate: 0.4 mL/min
pressure: 1305 psi (90 bar)
column temp.: 35 °C
detector: ESI(+), full scan, m/z 100-1000
injection: 0.5 μL
sample: plasma extract, analyte concentration of final sample work-up is equivalent to 100 ng/mL

Eignung

application for HPLC
application for SPE

Anwendung(en)

clinical

Hinweis zur Analyse

The basic characteristics of antiarrhythmic cardiac drugs and associated metabolites make them targets for HILIC chromatographic separation. HILIC mobile phases consist of a high composition of acetonitrile which facilitates the direct analysis of precipitated plasma samples without the need for additional sample solvent exchange. In most cases, the high organic mobile phase also increases analyte response with ESI(+) MS detection. This application used HybridSPE-Phospholipid sample prep to remove phospholipids and precipitated proteins prior to LC/MS analysis on Ascentis Express HILIC. These chromatograms compare the response with HybridSPE-Phospholipid vs. standard protein precipitation sample prep methods. The highest grade solvents provided clean, robust operation. Cerilliant CRMs provided reliable quantification.

Rechtliche Hinweise

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany
HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany

Analyt

Beschreibung

    Amiodarone hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
    N-Desethylamiodarone hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
    Lidocaine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
    (±)-Flecainide solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Leider sind derzeit keine COAs für dieses Produkt online verfügbar.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.